Trial · NCT00741286
Effect of Cilostazol in the Acute Lacunar Infarction Based on Pulsatility Index of Transcranial Doppler
NCT00741286, Phase 4, Completed, Inje University; results first posted 2011-09-05
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Effect of Cilostazol in the Acute Lacunar Infarction Based on Pulsatility Index of Transcranial Doppler. Trials, record NCT00741286. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00741286
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Effect of Cilostazol in the Acute Lacunar Infarction Based on Pulsatility Index of Transcranial Doppler
- NCT number
- NCT00741286
- Status
- Completed
- Phases
- Phase 4
- Enrollment
- 203 participants, actual
- Lead sponsor
- Inje University
- Conditions
- Cerebral Infarction
- Interventions
- Aspirin, cilostazol
- First posted
- 2008-08-26
- Last updated
- 2011-09-05
- Results first posted
- 2011-09-05
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | The Changes of Middle Cerebral Artery (MCA) and Basilar Artery (BA) Pulsatility Index (PI) at 14 and 90 Days From the Baseline Transcranial Doppler (TCD) Study | 14 days and 90 days from the baseline TCD study | The PI is designed to measure vascular resistance and characterizes the shape of the spectral waveform. For the study, the mean, systolic, and diastolic flow velocities were measured using TCD. Gosling's PI was determined as the difference between the peak systolic and end-diastolic velocities divided by the mean flow velocity in each artery.The changes of MCA and BA PIs at 14 and 90 days from the baseline TCD study was calculated for the study. |
| Secondary | Number of Patients With First Recurrent Stroke of Any Type | 90 days |
Source ClinicalTrials.gov
Outcomes2
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | The Changes of Middle Cerebral Artery (MCA) and Basilar Artery (BA) Pulsatility Index (PI) at 14 and 90 Days From the Baseline Transcranial Doppler (TCD) Study | 14 days and 90 days from the baseline TCD study | Of the 203 patients included in the intention-to-treat analysis, 164 were included in the per-protocol analysis of the primary outcome. | ratio | MEAN |
| SECONDARY | Number of Patients With First Recurrent Stroke of Any Type | 90 days | participants | NUMBER |
Source ClinicalTrials.gov
Results by group14
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| The Changes of Middle Cerebral Artery (MCA) and Basilar Artery (BA) Pulsatility Index (PI) at 14 and 90 Days From the Baseline Transcranial Doppler (TCD) Study | Asprin Plus Placebo | Changes of PI in Right MCA (14 days) | 0.07 | Standard Deviation 0.13 | ratio |
| The Changes of Middle Cerebral Artery (MCA) and Basilar Artery (BA) Pulsatility Index (PI) at 14 and 90 Days From the Baseline Transcranial Doppler (TCD) Study | Asprin Plus Cilostazol | Changes of PI in Right MCA (14 days) | 0.08 | Standard Deviation 0.13 | ratio |
| The Changes of Middle Cerebral Artery (MCA) and Basilar Artery (BA) Pulsatility Index (PI) at 14 and 90 Days From the Baseline Transcranial Doppler (TCD) Study | Asprin Plus Placebo | Changes of PI in Right MCA (90 days) | 0.09 | Standard Deviation 0.13 | ratio |
| The Changes of Middle Cerebral Artery (MCA) and Basilar Artery (BA) Pulsatility Index (PI) at 14 and 90 Days From the Baseline Transcranial Doppler (TCD) Study | Asprin Plus Cilostazol | Changes of PI in Right MCA (90 days) | 0.14 | Standard Deviation 0.13 | ratio |
| The Changes of Middle Cerebral Artery (MCA) and Basilar Artery (BA) Pulsatility Index (PI) at 14 and 90 Days From the Baseline Transcranial Doppler (TCD) Study | Asprin Plus Placebo | Changes of PI in Left MCA (14 days) | 0.08 | Standard Deviation 0.13 | ratio |
| The Changes of Middle Cerebral Artery (MCA) and Basilar Artery (BA) Pulsatility Index (PI) at 14 and 90 Days From the Baseline Transcranial Doppler (TCD) Study | Asprin Plus Cilostazol | Changes of PI in Left MCA (14 days) | 0.1 | Standard Deviation 0.14 | ratio |
| The Changes of Middle Cerebral Artery (MCA) and Basilar Artery (BA) Pulsatility Index (PI) at 14 and 90 Days From the Baseline Transcranial Doppler (TCD) Study | Asprin Plus Placebo | Changes of PI in Left MCA (90 days) | 0.07 | Standard Deviation 0.13 | ratio |
| The Changes of Middle Cerebral Artery (MCA) and Basilar Artery (BA) Pulsatility Index (PI) at 14 and 90 Days From the Baseline Transcranial Doppler (TCD) Study | Asprin Plus Cilostazol | Changes of PI in Left MCA (90 days) | 0.13 | Standard Deviation 0.13 | ratio |
| The Changes of Middle Cerebral Artery (MCA) and Basilar Artery (BA) Pulsatility Index (PI) at 14 and 90 Days From the Baseline Transcranial Doppler (TCD) Study | Asprin Plus Placebo | Changes of PI in BA (14 days) | 0.09 | Standard Deviation 0.14 | ratio |
| The Changes of Middle Cerebral Artery (MCA) and Basilar Artery (BA) Pulsatility Index (PI) at 14 and 90 Days From the Baseline Transcranial Doppler (TCD) Study | Asprin Plus Cilostazol | Changes of PI in BA (14 days) | 0.09 | Standard Deviation 0.14 | ratio |
1 to 10 of 14Source ClinicalTrials.gov
See all 14 results by groupParticipant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Asprin Plus Placebo | 103 | |
| Overall Study | STARTED | Asprin Plus Cilostazol | 100 | |
| Overall Study | COMPLETED | Asprin Plus Placebo | 83 | |
| Overall Study | COMPLETED | Asprin Plus Cilostazol | 81 | |
| Overall Study | NOT COMPLETED | Asprin Plus Placebo | 20 | |
| Overall Study | NOT COMPLETED | Asprin Plus Cilostazol | 19 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Asprin Plus Placebo | ||
| Total, all-cause mortality | Asprin Plus Cilostazol | ||
| Total, other adverse events | Asprin Plus Placebo | 0 | 103 |
| Total, other adverse events | Asprin Plus Cilostazol | 0 | 100 |
| Total, serious adverse events | Asprin Plus Placebo | 0 | 83 |
| Total, serious adverse events | Asprin Plus Cilostazol | 0 | 81 |
Source ClinicalTrials.gov
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 23128968 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons2
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
| Asprin Plus Placebo vs Asprin Plus Cilostazol: Number of Patients With First Recurrent Stroke of Any Type | Trial comparisons |
| Asprin Plus Placebo vs Asprin Plus Cilostazol: serious adverse events | Trial comparisons |
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00741286
GET https://conductscience.org/api/trials/v1/NCT00741286/registered